Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signals Ask the Agent

TPSTBullishEarningsShort Term

High materiality8/10

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

StockNews.AIAug 13, 4:25 PM EDT1 source

Trading thesisImportance 8/10

Bullish on TPST from late-2026 TPST-4003 dosing and 1H2027 data; funding risk could constrain upside in the near term.

AI summary

What happened and why it matters

Tempest Therapeutics unveiled Q2 2026 results and a collaboration with Hebei Senlang Biotechnology to advance TPST-4003, a CD19/BCMA dual-target in vivo CAR-T, with first patient dosing expected in Q4 2026 and initial data in H1 2027. The company also reported strong TPST-2003 interim results and appointed new board members, while cash remains tight at $0.8 million, highlighting near-term funding needs.

Senlang collaboration may unlock China/Asia opportunities for TPST-4003.
TPST-2003 interim data showing 100% CR supports platform credibility.
New governance and BD hires signal strategic refocus and partnerships.
Low near-term cash runway increases financing risk and potential dilution.

Sentiment rationale

Positive data (TPST-2003 CR rate, TPST-4003 collaboration) and clear near-term catalysts (Q4 2026 dosing, H1 2027 data) can drive upside; however, near-term funding needs and a tight cash runway may cap upside and invite dilution, creating a mixed-risk setup typical for a clinical-stage biotech during catalysts.

Key facts

01
Tempest reports Q2 2026 results; updates on Senlang collaboration.
02
TPST-4003 lead candidate; first patient dosing expected Q4 2026.
03
TPST-2003 interim results: 100% CR in 15 evaluable patients; favorable safety.
04
Warrant inducement raises $2.0m; two independent directors join the board.
05
Cash on hand $0.8m as of 6/30/2026; ongoing asset acquisition costs.

Earnings

Category: Earnings and Corporate Developments. The release centers on quarterly results and strategic actions (collaboration, manufacturing, leadership changes) that influence TPST's near-term catalysts and long-term valuation.